Zobrazeno 1 - 10
of 4 055
pro vyhledávání: ''
Autor:
Rodolfo Montironi, Matteo Santoni, Matteo Rosellini, Francesco Massari, Andrea Ardizzoni, Veronica Mollica, Alessandro Rizzo, Andrea Marchetti, Angela Dalia Ricci
Publikováno v:
European Urology Focus. 8:514-521
Immune checkpoint inhibitors (ICIs) have reported unprecedented results in the treatment of metastatic renal cell carcinoma (mRCC) patients, as monotherapy or in combination with other anticancer agents. However, little information is available regar
Autor:
Ming Li, Quan Li, Ni Liu, Frances A. Shepherd, Teklab Gebregiworgis, Ming-Sound Tsao, Nadeem Moghal, Nhu-An Pham, Mitsuhiko Ikura, Ningdi Feng Liu, Zhenhao Fang, Hirotsugu Notsuda, Ku-Geng Huo, Christopher B. Marshall
Publikováno v:
Journal of Thoracic Oncology. 17:277-288
Introduction Mutations in BRAF occur in 2-4% of lung adenocarcinoma (LUAD) patients. Combination dabrafenib/trametinib or single-agent vemurafenib is approved only for patients with cancers driven by the V600E BRAF mutation. Targeted therapy is not c
Autor:
Kenneth K.-S. Ng, A. Iqbal, Mark G. Kris, Maria E. Arcila, Helena A. Yu, Linda Ahn, Jia Luo, Yosef Tobi, Sara A. Hayes, Alex Makhnin, Gregory J Riely
Publikováno v:
JCO Precision Oncology. :55-64
PURPOSE Inhibition of the MEK/ERK pathway is critical for Bcl-2-like protein 11 (BIM)-mediated epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-induced apoptosis, and dysregulation of this pathway may be a mechanism of acquired
Autor:
Hailing Cheng, Pixu Liu, Li Li, Zhiwei Tao, Zundong Liu, Yichao Liu, Xiaolin Sang, Chunhua Rui
Publikováno v:
Cancer Letters. 518:82-93
Despite HER2-targeted cancer treatments have provided considerable clinical benefits, resistance to HER2-targeted agents will inevitably develop. Targeting non-oncogene vulnerabilities including endoplasmic reticulum (EnR) stress has emerged as an at
Autor:
Johanna Lilja, Ella-Maria Vesilahti, Johanna M. Anttila, Hussein Al-Akhrass, Johanna Ivaska, Emilia Peuhu, Pauliina Munne, Mika Pietilä, Juha Klefström, Heidi M. Haikala
Publikováno v:
Molecular Oncology
Molecular Oncology, Vol 16, Iss 1, Pp 116-129 (2022)
Molecular Oncology, Vol 16, Iss 1, Pp 116-129 (2022)
In breast cancer, the currently approved anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) therapies do not fully meet the expected clinical goals due to therapy resistance. Identifying alternative HER2‐related therapeutic targets could off
Autor:
Philip He, Robin Kate Kelley, Ho Yeong Lim, Takuji Okusaka, Thomas Yau, David Wai-Meng Tai, Ghassan K. Abou-Alfa, Masafumi Ikeda, Bruno Sangro, Yoon-Koo Kang, Silvia Damian, Johanna C. Bendell, Mitesh J. Borad, William P. Harris, Tae-You Kim, Shukui Qin, Alejandra Negro, Mallory Makowsky, Nathan Standifer, Masatoshi Kudo, Ann-Lii Cheng, Jordi Bruix, Antonio Gasbarrini, Wei Peng Yong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 27
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unre
Autor:
Kazuharu Kai, Krina K. Patel, Lihua E. Budde, Hayder Saeed, Cameron J. Turtle, Nina Shah, Alan Tan, Andrew J. Cowan, Jonathan Zalevsky, Mitchell S. Cairo, Zachary J. Lee, Mary Tagliaferri, Mario Q. Marcondes, Miguel-Angel Perales
Publikováno v:
Future Oncology. 17:3549-3560
NKTR-255 is an investigational polyethylene glycol-modified recombinant human IL-15 (rhIL-15) receptor agonist, designed to improve the immunotherapeutic and anti-cancer benefit observed with rhIL-15 while circumventing the toxicities associated with
Autor:
Hongyun Zhao, Wenxiu Yao, Xuhong Min, Kangsheng Gu, Guohua Yu, Zhonghan Zhang, Jiuwei Cui, Liyun Miao, Li Zhang, Xia Yuan, Yong Fang, Xiuhua Fu, Chengping Hu, Xiaoli Zhu, Yun Fan, Qitao Yu, Gang Wu, Ou Jiang, Xiuping Du, Jiwei Liu, Wei Gu, Zhiguo Hou, Quanren Wang, Rongrong Zheng, Xianfeng Zhou
Publikováno v:
Journal of Thoracic Oncology. 16:1533-1546
Introduction Blocking vascular endothelial growth factor pathway can enhance the efficacy of EGFR tyrosine kinase inhibitors in EGFR-mutant NSCLC. ACTIVE is the first phase 3 study conducted in the People's Republic of China evaluating apatinib, a va
Autor:
Silvia Olivari, Gary Binder, Erminio Bonizzoni, Eric Roeland, Rudolph M. Navari, Rebecca Clark-Snow
Publikováno v:
Future Oncology. 17:3027-3035
Aim: In the absence of comparative studies, guidelines consider neurokinin 1 receptor antagonists (RAs) as interchangeable. We evaluated the pooled efficacy from three cisplatin registration trials, each with arms containing netupitant/palonosetron (
Autor:
Stephen V. Liu
Publikováno v:
Lung Cancer. 158:25-28
NRG1 fusions are rare oncogenic drivers that exist at low frequencies across multiple tumor types. They are uncommon in lung cancer with an estimated incidence of 0.2 %. NRG1 fusions have a unique biology and are challenging to detect, due to large i